FilingSEC EDGAR8-K
NRX Pharmaceuticals' ANDA Amendment Reclassified as Minor
· SEC accepted
StageUnder Review
Filing content
The FDA reclassified the company's ANDA amendment as a Minor Amendment and revised the GDUFA goal date to November 10, 2026.
AI summary of the filing. Please also check the source.Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…